Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesAKI: KELI-101 for Prevention of Acute Kidney Injury Post-Cardiac Surgery
NCT06678399Phase 2Not yet recruiting
- Sponsor
- Kelifarma
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 2, randomised, double-blind trial of KELI-101 in acute kidney injury (AKI) (5 arms), sponsored by Kelifarma. Primary endpoints: Treatment-emergent adverse events at Day 90 and Ratio of the acute kidney disease leading to chronic kidney disease at Day 90. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
KELI-101
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06678399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678399.